Literature DB >> 23126274

Detection of the GD2+/CD56+/CD45- immunophenotype by flow cytometry in cerebrospinal fluids from a patient with retinoblastoma.

Hongqiang Shen1, Yongmin Tang, Xiaojun Xu, Hongfeng Tang.   

Abstract

Triple-color flow cytometry with a panel of antibodies comprising GD2, CD56, and CD45 was performed to analyze cerebrospinal fluids (CSF) from a patient with retinoblastoma who was suspicious of meningeal metastasis based on clinical presentation. Our results showed that the cells in CSF demonstrated the immunophenotype positive for GD2 and CD56 but negative for CD45 antigen, which suggested the presence of CSF metastasis of retinoblastoma. At the end of eight cycles of intrathecal chemotherapy, CSF specimen was analyzed with Flow cytometry immunophenotyping (FCI) again and the result showed no detectable malignant cells with the same immunophenotype. Our conclusion is that FCI can be a quick and reliable method for the diagnosis of CSF metastasis of retinoblastoma and the immunophenotype (GD2+, CD56+, and CD45-) can be used to recognize residual retinoblastoma cells in CSF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23126274     DOI: 10.3109/08880018.2012.737094

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

1.  Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.

Authors:  Huixue Wang; Jie Yang; Hui Pan; Mei Chee Tai; Mohamed H Maher; Renbing Jia; Shengfang Ge; Linna Lu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

Review 2.  Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future.

Authors:  Ling Wang; Shixu Li; Jun Mei; Lin Ye
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

3.  Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry.

Authors:  Hongqiang Shen; Yongmin Tang; Ao Dong; Huamei Li; Diying Shen; Shilong Yang; Hongfeng Tang; Weizhong Gu; Qiang Shu
Journal:  Oncol Lett       Date:  2014-02-04       Impact factor: 2.967

Review 4.  Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy.

Authors:  Bassel Nazha; Cengiz Inal; Taofeek K Owonikoko
Journal:  Front Oncol       Date:  2020-07-07       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.